

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY DISCLOSURE**  
**2022 THIRD QUARTER UPDATE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to provide a voluntary disclosure on selected unaudited operational and financial information of the Group for the three months ended 30 September 2022.

In the third quarter 2022, with the pandemic gradually getting under control and production resuming normal, pharmaceutical consumption and patients’ visit to hospital for treatment rebounded significantly. The Group grasped the opportunity of recovery to accelerate the pace of research and development, manufacturing, and sales, which helped boost the Group’s rapid recovering growth in the third quarter. In the third quarter 2022, the Group recorded revenue (unaudited) of approximately RMB7,473.31 million, an increase of approximately 21.3% over the same period last year; in the first three quarters 2022, the Group recorded revenue (unaudited) of approximately RMB22,667.04 million, an increase of approximately 10.5% over the same period last year.

The Group has already made systematic arrangements in various aspects such as marketing system and production cost control, which has played a positive role in stabilising revenue and profit growth, to cope with the normalisation of national centralised procurement. In the future, the Group will build a healthier, more diversified and sustainable revenue structure by continuing to build on traditional public hospital sales and invest more resources in new marketing channels and new marketing tools, gradually expanding their share of revenue.

In view of the potential impact of the national centralised procurement policy on generic drugs, the Group has re-evaluated and optimised its product lines under development from the perspective of innovation and market value, focusing more on products with high innovation and market potential. The Group has also continued to invest more resources in innovative research and development facilities, personnel and projects. Innovation has become a key driver of growth for the Group, with the share of revenue from innovative medicines expected to reach 24% by 2022. Looking ahead, the Group plans to exceed the RMB10 billion mark in revenue from innovative medicines by 2023, further increasing the share of revenue from innovative medicines. The Group aims to become a world-class innovative pharmaceutical group by 2030, with a revenue target of HK\$100 billion, of which over 60% will be contributed by innovative drugs. The Group is focusing on four therapeutic areas, namely oncology, surgery/analgesia, liver disease and respiratory system, and will strive to achieve its 2030 target through a two-pronged approach of independent research and development and innovation-driven business development.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 2 November 2022

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*